The life sciences industry is eyeing a generative artificial intelligence (AI)-enabled future. It started with a thought experiment but now has moved to delivering impactful results in various areas. AI tools have played a crucial role in the go-to-market strategy for the launch of new drugs. Its direct impact is on life sciences organizations and customer relationships.
Top market leaders in the life sciences industry are exploring the growth opportunities with generative AI in life sciences. They are not only employing AI in ideation but also to pilot new projects. The deliberate move is to scale the use of AI in real-world applications. This is reflected in increased professional use of AI in the life sciences industry. However, there is a huge gap in the overall adoption by the majority of the industry. Its adoption rate will decide true personalization for the end consumer.
Where are generative AI solutions used in life sciences?
The priority of the task to be addressed and the feasibility of implementation of AI solutions go hand in hand. So, generative AI in life sciences is used in various areas, such as:
- Insight mining
- Creative concept building
- Strategic choices and planning
- Medical-legal regulatory review (MLR)
- Training and upskilling
- Salesforce execution
Use cases of AI implementation in life sciences
Many life sciences organizations are preparing for full adoption of AI in all organizational areas. They are relying on healthcare consulting to navigate this journey. These consulting firms come with years of expertise in guiding companies to make the right strategic decisions. They also use AI and advanced technological solutions to base their expert opinion on short-term and long-term organizational goal fulfillment.
Some of the prominent use cases where AI is shaping the life sciences industry are:
Gen AI agents for concept creation
Top leaders in life sciences organizations are directing marketers to use gen AI agents to accelerate the concept creation part for marketing new drugs on the market. They have seen fruitful results with better quality concepts that helped tremendously in awareness and marketing campaigns. The time taken to come up with the concept was also less compared to all human effort.
In-house content derivative generation
One of the key areas where AI tools have given positive results is in-house content derivative generation. Life sciences companies are using AI to optimize derivative content for new campaigns. They are using traditional and modern ways to market their drugs to the target group. While agency collaboration is still in place for initial asset products, AI tools are used for refining copy, imagery, and channel specifications. It is a big move in the accelerative go-to-market timeline of the new drug. Modular content adoption and automation enhancements are in place for in-house content derivative generation.
Insight mining by integrating primary and secondary data
Insight mining is an important part of the drug development and marketing process. Generative AI is used in life sciences for this purpose. It is employed to integrate primary and secondary data. Large language models help in extracting relevant data from market research files. AI models clean unstructured and structured data and combine it in one place to be used by researchers and marketers.
What are the barriers to the adoption of generative AI in life sciences?
Activities outsourced to agencies
Activities are outsourced to agencies, which limit direct control over the adoption and use of generative AI in life science organizations. This can slow down implementation and reduce consistency in AI-driven work.
Reluctancy among marketers
Many marketers are still hesitant to use AI tools and see them as a threat that can take up their jobs. They do not approach AI as a support system, which leads to a delayed adoption rate. It also reduces confidence in new technologies.
Rapidly evolving technology
There is a rapid evolution of AI technology. This makes it difficult for organizations to adopt the latest technology with constant updates, new tools, and changing capabilities.
Data-related risks
There are major data-related concerns, such as data privacy, security, and regulatory compliance. These data risks are huge barriers to the adoption of generative AI in the life sciences sector.
Need for talent upskilling
Implementing AI in different organizational functions in the life sciences sector requires talent upskilling. Employees must be trained to use AI as a support system to achieve daily tasks and organizational goals.
Inaccurate outputs
Generative AI can sometimes produce inconsistent outputs. It raises questions about its reliability and accuracy. So, life sciences companies face challenges in using AI in critical processes.
What are the next steps for adopting AI in life sciences?
Life sciences companies can place certain practices in place to accelerate the adoption of AI. It is not just a tool but an interconnected ecosystem. Here are some of the ways its adoption can be sped up:
- Strong leadership commitment: Leadership should remain committed to developing technological capabilities. It can be used in operating models, data strategy, compliance, and training.
- Rethinking the talent model: It is important to bring in expert talent from other industries to build internal AI capabilities in life sciences companies. There needs to be a mindset shift in employees to upskill and contribute to data-driven decision-making.
- Agentic workflow enablement: It is the right time to build multiple foundational use cases, such as MLR review and derivative content generation. It allows life sciences companies to build an interconnected system of AI.
Life sciences companies have come a long way when it comes to the adoption of AI. There are early adoption challenges, but they can be resolved by following a systematic process. In 2026, life sciences companies have begun to realize the huge potential of AI in all areas of research, marketing, and sales. Their approach towards implementing AI in key areas is going to be the deciding factor on how quickly they can leverage the full potential of AI. Not to forget, first movers in the industry will have a significant advantage in marketing their products to the target group and will be ahead in the game. Companies can scale their business by identifying many areas where work can be optimized with time efficiency, cost-effectiveness, and error-free operations.
Author Bio:
The author has 12 years of experience in the healthcare consulting industry. He has authored many articles, guest posts, and research papers on the latest industry updates.
